Psoriasis News and Research

Latest Psoriasis News and Research

Coding variants in immune disease-related genes play only small part in risk for psoriasis

Coding variants in immune disease-related genes play only a small part in the overall genetic risk for psoriasis, according to a new study led by Anhui Medical University and BGI.

10 Nov 2013

Four-year study to develop targeted approach to psoriasis treatment

A world-leading taskforce led by The University of Manchester has begun work to create a new test to help medics work out which treatment plan is most likely to improve the disabling skin condition psoriasis, based on a patient's individual biological make-up.

8 Nov 2013

PhotoMedex third quarter 2013 revenues decrease 19% to $45.9 million

PhotoMedex, Inc. today reported financial results for the three and nine months ended September 30, 2013.

6 Nov 2013

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.

4 Nov 2013

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD').

29 Oct 2013

IFPA brings attention to the need for improving treatment, care for psoriasis

Today, on World Psoriasis Day, the International Federation of Psoriasis Associations, IFPA, brings attention to the need for improving the availability of treatment and care for psoriasis - a disease that affects more than 125 million people all over the world.

29 Oct 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Incyte Corporation (Nasdaq: INCY) announced results from a 12-week, placebo-controlled, dose-escalationin involving 60 patients with active rheumatoid arthritis for its proprietary oral JAK1 inhibitor.

29 Oct 2013

DPP-4 inhibitors may reduce risk of autoimmune diseases

Dipeptidyl peptidase-4 inhibitors commonly used to control blood sugar levels in people with type 2 diabetes may also reduce the risk of autoimmune diseases in these patients, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Tumor necrosis factor inhibitor drugs (commonly called Anti-TNFs) modestly reduce the risk of acute coronary syndrome, such as heart attacks and angina, in rheumatoid arthritis patients whose inflammation places them at higher risk of developing coronary heart disease, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Anacor Pharmaceuticals appoints arbitrator to resolve its dispute with Valeant Pharmaceuticals

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that the arbitrator appointed to resolve its dispute with Valeant Pharmaceuticals, Inc. (Valeant), successor in interest to Dow Pharmaceutical Sciences, Inc. (DPS), has issued an Interim Final Award in favor of Anacor, awarding Anacor $100 million in damages as well as all costs of the arbitration and reasonable attorney's fees.

18 Oct 2013

New discovery may lead to effective treatments for chronic itching

Anyone who has suffered through sleepless nights due to uncontrollable itching knows that not all itching is the same. New research at Washington University School of Medicine in St. Louis explains why.

16 Oct 2013

New injection device to reduce fear and pain of injecting modern medicines

...

15 Oct 2013

National autoimmune disease multi-city conference tour to arrive in Charleston, SC on November 2

A National autoimmune disease multi-city conference tour arrives in Charleston, SC on Saturday, November 2, 2013. The conference "What Every American Needs to Know About Autoimmune Disease," is one of a series of free patient forums hosted by the American Autoimmune Related Diseases Association.

15 Oct 2013

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

14 Oct 2013

Finding highlights new ways of treating inflammation disorders

A team led by scientists at The Scripps Research Institute (TSRI) has identified key signaling proteins in the inflammation process that contribute to the development of inflammatory diseases such as rheumatoid arthritis, psoriasis, sepsis and inflammatory bowel diseases.

11 Oct 2013

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Pfizer Inc. announced today top-line results from two Phase 3 clinical trials of tofacitinib, a novel, oral Janus kinase inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A3921111).

10 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

PhotoMedex introduces NEOVA's hyper-active moisturizer, DNA Barrier Accelerator

PhotoMedex, the leader in photodamage repair technology, clinical skincare and medical laser products for more than a decade, introduces NEOVA® SmartSkinCare brand's DNA Barrier Accelerator, a hyper-active moisturizer that rehabilitates and fortifies the skin's essential protective barrier. DNA Barrier Accelerator is available for purchase in dermatology offices nationwide and on NEOVA.com.

4 Oct 2013

J&J's Janssen Companies Launch A Trio Of Collaborations

...

3 Oct 2013

Psoriasis News and Research

Latest Psoriasis News and Research

Coding variants in immune disease-related genes play only small part in risk for psoriasis

Four-year study to develop targeted approach to psoriasis treatment

PhotoMedex third quarter 2013 revenues decrease 19% to $45.9 million

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

IFPA brings attention to the need for improving treatment, care for psoriasis

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

DPP-4 inhibitors may reduce risk of autoimmune diseases

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Anacor Pharmaceuticals appoints arbitrator to resolve its dispute with Valeant Pharmaceuticals

New discovery may lead to effective treatments for chronic itching

New injection device to reduce fear and pain of injecting modern medicines

National autoimmune disease multi-city conference tour to arrive in Charleston, SC on November 2

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Finding highlights new ways of treating inflammation disorders

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

PhotoMedex introduces NEOVA's hyper-active moisturizer, DNA Barrier Accelerator

J&J's Janssen Companies Launch A Trio Of Collaborations

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Psoriasis News and Research

Latest Psoriasis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in